The difference between Avatrombopag and Hetrombopag

Avatrombopag (Avatrombopag) and Herombopag (Herombopag) are two different drugs, but both belong toTPO-RAs drugs. There are some differences in their ingredients, indications, administration methods, side effects and clinical research. Ifthe patient needs to use one of these drugs, it is recommended that treatment be carried out under the guidance of a doctor. Both avatrombopag and heltrombopag have undergone clinical trials and have been shown to be effective in increasing platelet counts and improving patient symptoms. However, the long-term safety and effectiveness of these drugs are still being studied.

Avatrombopag is a selective thrombopoietin receptor agonist (TPO-RAs) that increases platelet numbers by stimulating platelet production in the bone marrow and is approved for the treatment of chronic immune thrombocytopenia (ITP) in adults and for the treatment of thrombocytopenia in adults with chronic liver disease scheduled for surgery. Avatrombopag is administered as an oral tablet once daily. Hetrombopag is also a TPO-RAs with a similar mechanism of action and has a wider range of indications. In addition to ITP, it is also used for the treatment of thrombocytopenia in patients with cirrhosis. Hetrombopag is given as an injection, usually once a week or less frequently.

The original drug of avatrombopag has been launched in China and has entered the scope of Class B medical insurance, but it is only reimbursed for eligible patients. The price of a common specification of 20mg*15 tablets may be more than 7,000 yuan per box, while the original drug of avatrombopag marketed overseas is even more expensive. It is understood that there are generic drugs of avatrombopag available overseas, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of a box of 20mg*30 tablets in Laos pharmaceutical production specifications may be around RMB 1,000 (the price may fluctuate due to exchange rates).